Ear, Nose, Mouth and Throat Malignancy with MCC DRG Reimbursement

DRG 146 groups inpatient encounters for ear, nose, mouth, and throat malignancy with Major Complication or Comorbidity; it captures complex head and neck cancer care with significant resource needs. This grouping matters for inpatient reimbursement because the Major Complication or Comorbidity designation increases expected resource consumption and payment under Medicare.

DRG 146 Overview

DRG 146 covers inpatient admissions for malignant neoplasms of the ear, nose, mouth, and throat with Major Complication or Comorbidity present. Typical cases include complex head and neck cancer surgeries, extensive resections, or major complications requiring intensive management. This Diagnosis-Related Group drives higher Medicare reimbursement because the presence of a Major Complication or Comorbidity substantially increases resource use and length of stay. Accurate coding of the primary tumor site, procedures, and accompanying Major Complication or Comorbidity is central to payment assignment.

Phase II/III neoadjuvant and adjuvant therapy trials exploring combined modality regimens for advanced head and neck cancers (oral cavity, oropharynx, larynx, hypopharynx, nasal cavity/paranasal sinuses) with major comorbidities: these studies assess the safety, tumor response, and surgical resectability after systemic therapy and/or chemoradiation given before or after surgery in patients who present with locally advanced disease and significant medical complexity. They enroll inpatient surgical candidates who often require perioperative optimization and intensive post‑operative care; findings inform clinicians about operative timing, complication risks, and potential to downstage tumors. For payers and hospital administrators, results guide resource allocation for high‑cost combined treatments, length of stay expectations, and reimbursement planning tied to complication avoidance and readmission reduction.
Comparative effectiveness trials evaluating different surgical approaches and perioperative pathways for head and neck malignancies in high‑risk patients: randomized or pragmatic trials compare open resection versus transoral or minimally invasive approaches, or test enhanced recovery after surgery (ERAS) protocols versus standard care in patients with advanced ENT malignancies and major comorbid conditions (e.g., cardiovascular or pulmonary disease). These studies focus on intraoperative blood loss, airway management needs, postoperative complication rates (including wound, fistula, and aspiration), functional outcomes (speech, swallowing), and short‑term resource use such as ICU stays. Results are directly relevant to surgeons, anesthesiologists, and payers because they impact inpatient utilization, complication‑related costs, selection of surgical technique by risk profile, and metrics that drive DRG payments.
Post‑discharge and survivorship outcomes research examining long‑term functional recovery, health‑related quality of life, and healthcare utilization after hospitalization for ENT malignancy with major complications: cohort studies and intervention trials evaluate swallowing rehabilitation, nutrition support strategies, tracheostomy decannulation protocols, and multidisciplinary care models to reduce readmissions and chronic care needs among patients discharged after complex head and neck cancer admissions. These studies target the heterogeneous population of survivors who had prolonged inpatient courses, ICU stays, or reconstructive surgery, and measure readmission rates, durable dependency on feeding tubes or ventilatory support, and outpatient service utilization. For providers and payers, evidence from these studies helps design care pathways that reduce downstream costs, improve functional outcomes, and inform bundled payment or value‑based care strategies for this high‑acuity DRG.

Phase II/III neoadjuvant and adjuvant therapy trials exploring combined modality regimens for advanced head and neck cancers (oral cavity, oropharynx, larynx, hypopharynx, nasal cavity/paranasal sinuses) with major comorbidities: these studies assess the safety, tumor response, and surgical resectability after systemic therapy and/or chemoradiation given before or after surgery in patients who present with locally advanced disease and significant medical complexity. They enroll inpatient surgical candidates who often require perioperative optimization and intensive post‑operative care; findings inform clinicians about operative timing, complication risks, and potential to downstage tumors. For payers and hospital administrators, results guide resource allocation for high‑cost combined treatments, length of stay expectations, and reimbursement planning tied to complication avoidance and readmission reduction.
Comparative effectiveness trials evaluating different surgical approaches and perioperative pathways for head and neck malignancies in high‑risk patients: randomized or pragmatic trials compare open resection versus transoral or minimally invasive approaches, or test enhanced recovery after surgery (ERAS) protocols versus standard care in patients with advanced ENT malignancies and major comorbid conditions (e.g., cardiovascular or pulmonary disease). These studies focus on intraoperative blood loss, airway management needs, postoperative complication rates (including wound, fistula, and aspiration), functional outcomes (speech, swallowing), and short‑term resource use such as ICU stays. Results are directly relevant to surgeons, anesthesiologists, and payers because they impact inpatient utilization, complication‑related costs, selection of surgical technique by risk profile, and metrics that drive DRG payments.
Post‑discharge and survivorship outcomes research examining long‑term functional recovery, health‑related quality of life, and healthcare utilization after hospitalization for ENT malignancy with major complications: cohort studies and intervention trials evaluate swallowing rehabilitation, nutrition support strategies, tracheostomy decannulation protocols, and multidisciplinary care models to reduce readmissions and chronic care needs among patients discharged after complex head and neck cancer admissions. These studies target the heterogeneous population of survivors who had prolonged inpatient courses, ICU stays, or reconstructive surgery, and measure readmission rates, durable dependency on feeding tubes or ventilatory support, and outpatient service utilization. For providers and payers, evidence from these studies helps design care pathways that reduce downstream costs, improve functional outcomes, and inform bundled payment or value‑based care strategies for this high‑acuity DRG.

OpenPayer

Summary & Overview

Ear, Nose, Mouth and Throat Malignancy with MCC: Inpatient Reimbursement Overview

DRG 146 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes